Morgan Stanley sees downside to 2026–27 consensus for Novo

ReutersSep 29, 2025 7:53 AM

View all comments（0）



Morgan Stanley cuts its rating on Danish drugmaker Novo Nordisk NOVOb.CO to "underweight" from "equal-weight", citing a "tough path ahead" due to rising competition

The broker sees downside to 2026-27 consensus estimates, forecasting slower prescription growth for Novo's GLP-1 drugs

MS highlights stagnating U.S. prescriptions for Ozempic and Wegovy amid "fierce competition" from rivals like Eli Lilly LLY.N, compounded drugs, and emerging generics

A risky catalyst path with potential downside includes the EVOKE Alzheimer's trial and the upcoming US Medicare Part D price announcement for its key drug semaglutide, MS adds

The brokerage cuts its PT by over a fifth to DKK 300, expecting valuation multiples to compress as the 2031-32 patent cliff for semaglutide approaches

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

Commenting Guidelines

Recommended Articles

Samsung’s Largest Strike in History: Can SK Hynix and Micron Sit Back and Reap the Benefits?

TradingKey - On May 21, 61,000 union members at Samsung Electronics will launch an 18-day general strike, following a 93.1% approval vote. Government mediation between labor and management has collapsed.

Inflation 'High Fever' Fails to Stop Rally? BTC Temporarily Loses 80,000 Mark, But Arthur Hayes Sees Peak of $126,000

Higher-than-expected CPI data triggered a Bitcoin drop below $80,000, but the BitMEX co-founder remains staunchly bullish on BTC.

Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

TradingKey - Cerebras Systems (CBRS) IPO prices May 13–14 at $125–$135/share. $26–$27B valuation, 20x oversubscribed, $510M revenue, 47% net margin, OpenAI 750MW deal. Everything you need to know.

SK Hynix Surges 15% to New High: HBM Shortage Until 2028, How Much Longer Can AI Memory King Rise?

TradingKey - During the Asian trading session on May 11, SK Hynix shares rose by more than 15% at one point, hitting an all-time intraday high of 1.949 million KRW, with its market capitalization surpassing $900 billion. The year-to-date cumulative gain is approximately 197.03%, with the share price nearly tripling.

AMD Q1 Earnings: Data Center Revenue Surges 57% Driving Results Above Estimates, Shares Rise Over 16% After Hours

TradingKey - On May 5 (ET), Advanced Micro Devices (AMD) released its first-quarter fiscal 2026 financial results after the market close. The company reported revenue of $10.253 billion, up 38% year-over-year, exceeding market expectations of $9.89 billion. Non-GAAP earnings per share (EPS) were $1.

Featured Tools